TriLink BioTechnologies, a Maravai LifeSciences company, and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding (MOU). This agreement is aimed at supporting the development of mRNA-based vaccines.
The collaboration signifies a joint effort to advance research and development in the field of mRNA vaccine technology. This partnership underscores TriLink's commitment to global health initiatives and expanding the applications of its nucleic acid technologies.
The MOU is expected to facilitate cooperative endeavors in addressing unmet medical needs through innovative vaccine solutions. This strategic alliance could open new avenues for TriLink's technologies in the global vaccine landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.